Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for paracetamol (IV formulation) the scientific conclusions are as follows:

Paracetamol overdose during pregnancy

Case reports and a systematic review of literature during the reporting period highlighted the potential fetal compromise in the context of maternal acetaminophen overdose. Based on a systematic review of the literature, a significant number of cases of acute maternal acetaminophen or paracetamol overdose in pregnancy were identified, with a 4% adverse fetal income including fetal abnormalities leading to termination of pregnancy, cases of non-reassuring fetal status leading to indicated delivery and cases of stillbirth. The following sentence *"Prospective data on pregnancies exposed to overdoses did not show an increase in malformation risk."* should be deleted from the Summary of Product Characteristics (SmPC) of paracetamol IV medicinal products as it is a reassuring message which does not allow health professionals to be aware of the potential of fetal compromise in the context of a maternal overdose. Moreover this statement is not supported by sufficient scientific evidence.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing paracetamol (IV formulation) is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing paracetamol (IV formulation) are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.6

~~Prospective data on pregnancies exposed to overdoses did not show an increase in malformation risk.~~

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	December 2018 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	26 January 2018
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	27 March 2018